Skip to main content

Table 2 Univariate and multiple COX analyses of overall survival in BC patients

From: Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer

Characteristics N Univariate analysis Multiple analysis
HR (95% CI) p-value HR (95% CI) p-value
Age
  ≤ 45 153 Ref   Ref  
  > 45 782 1.46 (0.81–2.65) 0.208 1.68 (0.88–3.20) 0.117
Ethnicity#
 Hispanic/Latino 32 Ref   Ref  
 Not Hispanic/Latino 744 21.83 (0.24–9.29) 0.178 NA 0.965
Pathological stage#
 I/II 707 Ref   Ref  
 III/IV 239 2.28 (1.45–3.61) 0.000* 1.51 (0.81–2.79) 0.195
Tumor size      
 T1/T2 797 Ref   Ref  
 T3/T4 157 1.39 (0.83–2.33) 0.207 0.89 (0.44–1.80) 0.753
Lymph node#
 Negative 444 Ref   Ref  
 Positive 494 2.04 (1.26–3.30) 0.004* 1.77 (0.97–3.20) 0.061
Distant metastasis#
 Negative 788 Ref   Ref  
 Positive 18 4.35 (2.16–8.75) 0.000* 2.54 (1.11–5.83) 0.028*
ER status#      
 Negative 264 Ref   Ref  
 Positive 667 1.02 (0.63–1.67) 0.925 0.99 (0.58–1.71) 0.981
PR status#
 Negative 161 Ref   Ref  
 Positive 772 2.88 (1.17–7.12) 0.022* 2.78 (1.11–6.98) 0.029*
HER2 status#      
 Negative 531 Ref   Ref  
 Positive 162 0.96 (0.54–1.71) 0.891 0.66 (0.34–1.30) 0.230
Molecular subtype      
 HR positive BC 808 Ref   Ref  
 HER-2 positive BC 36 2.68 (1.07–6.76) 0.036* 2.24 (0.80–6.30) 0.127
 TNBC 91 1.67 (0.90–3.11) 0.104 1.95 (1.01–3.77) 0.047*
Histological subtype#
 Infiltrating ductal BC 655 Ref   Ref  
 Infiltrating lobular BC 192 0.29 (0.12–0.66) 0.003* 0.42 (0.18–0.99) 0.049*
 Mixed BC 24 0.56 (0.14–2.31) 0.426 0.21 (0.03–1.57) 0.129
 Medullary BC 3 1.03 (0.25–4.32) 0.963 1.68 (0.39–7.14) 0.484
 Metaplastic BC 5 NA 0.977 NA 0.974
 Mucinous BC 16 2.18 (0.30–15.85) 0.441 3.86 (0.52–28.64) 0.187
 Others 39 1.07 (0.49–2.35) 0.872 0.99 (0.37–2.62) 0.983
FST expression
 Low 77 Ref   Ref  
 High 858 0.47 (0.27–0.82) 0.008* 0.40 (0.21–0.75) 0.004*
  1. #The composition ratio is less than 100%; *p < 0.05, statistical significance
  2. HR hazard ratio, CI confidence interval, HR positive BC, hormone receptor positive breast cancer; HER-2 positive BC, human epidermalgrowth factor receptor-2 positive breast cancer; TNBC triple-negative breast cancer